ALLN-346 for the Treatment of Gout in Chronic Kidney Disease
KOL webinar hosted by Allena Pharmaceuticals, Inc. (Nasdaq: ALNA)
June 16, 2021 12:00 pm ET
Allena Pharmaceuticals, Inc.
These slides, and the accompanying presentation, contain forward-looking statements and information. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward-looking statements. All forward-looking statements are based on estimates and assumptions by our management that, although we believe them to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected, including those risks and uncertainties that are described under the heading "Risk Factors" in our Quarterly Report on Form 10-Q for the three months ended March 31, 2021, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
This presentation also contains estimates and other statistical data made by independent parties and us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.
2
Agenda
- Welcome and Opening Remarks - Louis Brenner, M.D., President and Chief Executive Officer
- Key Opinion Leader - Robert Terkeltaub, M.D., Professor of Medicine, University of California San Diego
- Market Overview - Geoffrey Swire, Senior Vice President, Corporate Development
- ALLN-346Development Program - David J. Clark, M.D., Chief Medical Officer
- Q&A - All speakers
- Closing remarks - Louis Brenner, M.D., President and Chief Executive Officer
3
Leadership in Oral Enzyme Technology for Metabolic and Kidney Disorders
Formulation | Oral | Non- | GI Mechanism |
Technology | Enzymes | Absorbed | of Action |
Reloxaliase
ALLN-346
Enhanced stability | Therapeutic | Reduces | Leverage |
in the GI tract and | candidates that | potential for | GI tract as |
proprietary CMC | degrade a specific | adverse events | "auxiliary kidney" |
approach | metabolite |
Technology platform encompasses broad set of core competencies
4
First-in-Class Oral Biologics
Product | Indication | Discovery Preclinical Phase 1 | Phase 2 | Phase 3 | Next Milestone | Timing |
Reloxaliase | Enteric Hyperoxaluria | URIROX-2 Interim | 2Q/3Q- 2022 | |||
Analysis | ||||||
Hyperuricemia and | Phase 1b MAD Data | Q3 - 2021 | ||||
ALLN-346 | Gout with Chronic | Initial Phase 2a | ||||
Kidney Disease | ||||||
Program Data | Q4 - 2021 | |||||
Oral Enzyme | Metabolic Disease | Initiation of new | H2 - 2021 | |||
Candidate(s) | program | |||||
Allena has retained worldwide rights for all programs
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Allena Pharmaceuticals Inc. published this content on 16 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 July 2021 12:32:03 UTC.